{"disease":{"id":"non-alcoholic-steato-hepatitis","name":"non alcoholic steato hepatitis"},"drugs":{"marketed":[{"drug_id":"resmetirom","indication_name":"Noncirrhotic Nonalcoholic Steatohepatitis (NASH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RESMETIROM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Thyroid Hormone Receptor beta Agonist [EPC]","quality_score":30,"revenue":null,"mechanism":null}],"pipeline":[{"drug_id":"pf-05221304","indication_name":"Nonalcoholic steatohepatitis (NASH)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-05221304","generic_name":"pf-05221304","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Acetyl-CoA carboxylase (ACC1 and ACC2)","drug_class":"Acetyl-CoA carboxylase inhibitor","quality_score":27,"revenue":null,"mechanism":"Selective inhibitor of acetyl-CoA carboxylase (ACC1/ACC2) that reduces hepatic lipogenesis and promotes fatty acid oxidation."}],"offLabel":[],"totalMarketed":1,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT03151473","title":"Longitudinal Observational Study Of Chinese With NAFLD/NASH","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Humanity and Health Research Centre","has_results":false},{"nct_id":"NCT04442334","title":"The European NAFLD Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Newcastle University","has_results":false},{"nct_id":"NCT07336563","title":"ENDOCARE-SCREEN: Metabolic Liver Dysfunction Screening Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Jarosław Drobnik","has_results":false},{"nct_id":"NCT05423327","title":"Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)","phase":"NA","overall_status":"TERMINATED","enrollment_count":5311,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT04371042","title":"PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05029583","title":"Clinical Outcomes From Enhanced SCREENing Strategies for NASH in Type 2 Diabetes (SCREEN NASH T2D)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"LMC Diabetes & Endocrinology Ltd.","has_results":false},{"nct_id":"NCT05463796","title":"InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT02548351","title":"Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":2477,"lead_sponsor_name":"Intercept Pharmaceuticals","has_results":true},{"nct_id":"NCT03028740","title":"AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1778,"lead_sponsor_name":"Tobira Therapeutics, Inc.","has_results":true},{"nct_id":"NCT04822181","title":"Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1205,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03535142","title":"Prognostic Significance of Fatty Liver Disease in Bariatric Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Esbjerg Hospital - University Hospital of Southern Denmark","has_results":false},{"nct_id":"NCT04666402","title":"Integrated Diagnostics for Early Diagnosis of Liver Disease","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Manchester University NHS Foundation Trust","has_results":false},{"nct_id":"NCT03726827","title":"A Self Selected Population Study of Undiagnosed NAFLD and NASH, Using an Echosens FibroScan, in at Risk Populations","phase":"","overall_status":"COMPLETED","enrollment_count":1006,"lead_sponsor_name":"Fatty liver Foundation","has_results":false},{"nct_id":"NCT04849728","title":"A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Inventiva Pharma","has_results":false},{"nct_id":"NCT03439254","title":"Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":919,"lead_sponsor_name":"Intercept Pharmaceuticals","has_results":true},{"nct_id":"NCT03053063","title":"Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":883,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT03142867","title":"The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Adults","phase":"","overall_status":"TERMINATED","enrollment_count":826,"lead_sponsor_name":"The Geneva Foundation","has_results":false},{"nct_id":"NCT03053050","title":"Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":808,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT03289897","title":"Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan","phase":"NA","overall_status":"COMPLETED","enrollment_count":801,"lead_sponsor_name":"Perspectum","has_results":false},{"nct_id":"NCT04690972","title":"\"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases\".","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT04841057","title":"Biometabolic Outcomes After Weight Loss Surgery: An Individualized Approach","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":750,"lead_sponsor_name":"University of Missouri-Columbia","has_results":false},{"nct_id":"NCT05016882","title":"Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":698,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT05765890","title":"Barriers to MASLD Management in Europe: Findings From a Multidisciplinary HCP-survey","phase":"","overall_status":"COMPLETED","enrollment_count":675,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT04595474","title":"Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":533,"lead_sponsor_name":"Joslin Diabetes Center","has_results":false},{"nct_id":"NCT04653103","title":"NASH in Subjects With Different Classes of Obesity","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Catholic University of the Sacred Heart","has_results":false},{"nct_id":"NCT04971785","title":"Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":457,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT05301231","title":"Omics-based Predictors of NAFLD/Potential NASH","phase":"","overall_status":"UNKNOWN","enrollment_count":450,"lead_sponsor_name":"National Research Centre, Egypt","has_results":false},{"nct_id":"NCT05479721","title":"LITMUS Imaging Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":450,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT04571957","title":"Expanding Donor Pool for Live Donor Liver Transplantation: Utilization of Donors With NASH After Optimization","phase":"","overall_status":"COMPLETED","enrollment_count":410,"lead_sponsor_name":"Institute of Liver and Biliary Sciences, India","has_results":false},{"nct_id":"NCT07180745","title":"Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Badr University","has_results":false},{"nct_id":"NCT05023044","title":"Nonalcoholic Fatty Liver Disease in HIV Database","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT04012242","title":"Innovative Liver Elasticity, Attenuation, and Dispersion Ultrasound Study","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Tokyo Medical University","has_results":false},{"nct_id":"NCT03449446","title":"Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":395,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT05877547","title":"A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":381,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04365868","title":"Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":357,"lead_sponsor_name":"Galectin Therapeutics Inc.","has_results":false},{"nct_id":"NCT02855164","title":"Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":350,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03439189","title":"Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14","phase":"","overall_status":"COMPLETED","enrollment_count":343,"lead_sponsor_name":"Meridian Bioscience, Inc.","has_results":true},{"nct_id":"NCT03858920","title":"The Liver in the World Trade Center Health Program General Responder Cohort and Controls","phase":"","overall_status":"COMPLETED","enrollment_count":340,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":false},{"nct_id":"NCT03151798","title":"The Liver Health Study for Patients with NAFLD","phase":"NA","overall_status":"COMPLETED","enrollment_count":336,"lead_sponsor_name":"University of Missouri-Columbia","has_results":false},{"nct_id":"NCT02970942","title":"Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":320,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT02686762","title":"Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":318,"lead_sponsor_name":"Conatus Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT03248882","title":"Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":305,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04255069","title":"A Study to Evaluate the Efficacy and Safety of JKB-122 in Patients With NASH and Fibrosis","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"TaiwanJ Pharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT05499949","title":"The Franciscus Obesity NASH Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Franciscus Gasthuis","has_results":false},{"nct_id":"NCT04771273","title":"A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":295,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT02217475","title":"Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":289,"lead_sponsor_name":"Tobira Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03524365","title":"Bariatric Surgery Versus Non-alcoholic Steato-hepatitis","phase":"NA","overall_status":"COMPLETED","enrollment_count":288,"lead_sponsor_name":"Catholic University of the Sacred Heart","has_results":false},{"nct_id":"NCT04052516","title":"A Phase 2b Study of Icosabutate in Fatty Liver Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":280,"lead_sponsor_name":"NorthSea Therapeutics B.V.","has_results":true},{"nct_id":"NCT05357352","title":"Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis","phase":"","overall_status":"COMPLETED","enrollment_count":263,"lead_sponsor_name":"Methodist Health System","has_results":false},{"nct_id":"NCT02960204","title":"Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":263,"lead_sponsor_name":"Histogen","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}